A Clinical Study on Alopecia Areata
January 2018
in “
International journal of research in dermatology
”
Studysummary This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In a clinical study conducted on 45 patients with alopecia areata (AA), three treatment modalities were compared: oral mini pulse therapy with betamethasone, intralesional corticosteroids with triamcinolone acetonide, and platelet-rich plasma (PRP) therapy. The study was randomized and prospective, lasting 16 weeks. Results showed a reduction in the Severity of Alopecia Tool (SALT) score for all groups, with the scores decreasing from 13.27 to 7.52 in Group 1, 13.93 to 8.16 in Group 2, and 42.32 to 21.12 in Group 3. The mean grade of hair regrowth was 3.47 for Group 1, 3.80 for Group 2, and 2.93 for Group 3. The study concluded that intralesional corticosteroids remain the first choice of therapy for adults with limited AA, systemic corticosteroids are less effective than intralesional steroids, and PRP showed promising results, particularly in children and cases with extensive involvement, being safe and with fewer side effects.
